Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,858,650 protect, and when does it expire?

Patent ► Subscribe protects TOVIAZ and is included in one NDA. There has been one Paragraph IV challenge on Toviaz.

This patent has sixty-nine patent family members in twenty-nine countries.

Summary for Patent: ► Subscribe

Title:	Stable salts of novel derivatives of 3,3-diphenylpropylamines
Abstract:	The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
Inventor(s):	Meese; Claus (Monheim, DE)
Assignee:	Schwarz Pharma AG (DE)
Application Number:	10/130,214
Patent Claim Types: see list of patent claims	Compound; Formulation; Use;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Substance	Patented / Exclusive Use
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008	AB	RX	Yes	No	► Subscribe	► Subscribe	Y	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	AB	RX	Yes	Yes	► Subscribe	► Subscribe	Y	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	199 55 190	Nov 16, 1999

PCT Information
PCT Filed	November 15, 2000	PCT Application Number:	PCT/EP00/11309
PCT Publication Date:	May 25, 2001	PCT Publication Number:	WO01/35957

International Patent Family for Patent: ► Subscribe

Country	Document Number	Estimated Expiration
Poland	201422	► Subscribe
Poland	356766	► Subscribe
New Zealand	519230	► Subscribe
Norway	332637	► Subscribe
Norway	20065380	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview